Literature DB >> 2424291

The carcinoid syndrome: palliation by hepatic artery embolization.

C H Carrasco, C Charnsangavej, J Ajani, N A Samaan, W Richli, S Wallace.   

Abstract

A group of 25 patients with malignant carcinoid syndrome underwent hepatic artery embolizations to palliate the symptoms of this syndrome. Twenty-three patients could be evaluated: 20 (87%) of them responded to embolization with a median response duration of 11+ months, one (4%) did not respond, and two (9%) died of complications from the embolization. The symptomatic responses correlated with two variables: (1) a decrease in the extent of the hepatic metastases in 17 of the 18 patients who had follow-up hepatic imaging, and (2) a decrease in the urine 5-hydroxyindoleacetic acid values to a mean of 41% of pretreatment levels in the 18 patients for whom this test was available. Hepatic artery embolization provides the most effective treatment for the carcinoid syndrome and the hepatic metastases. Periodic embolizations will maintain clinical remissions for prolonged periods of time.

Entities:  

Mesh:

Year:  1986        PMID: 2424291     DOI: 10.2214/ajr.147.1.149

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  25 in total

1.  Liver Metastases.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

2.  High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

Authors:  Akira Yamamoto; Inna Chervoneva; Kevin L Sullivan; David J Eschelman; Carin F Gonsalves; Michael J Mastrangelo; David Berd; Jerry A Shields; Carol L Shields; Mizue Terai; Takami Sato
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

3.  Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.

Authors:  C C Case; K Wirfel; R Vassilopoulou-Sellin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 4.  Update in the Therapy of Advanced Neuroendocrine Tumors.

Authors:  Inbal Uri; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 5.  Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract.

Authors:  Magaly Zappa; Mohamed Abdel-Rehim; Olivia Hentic; Marie-Pierre Vullierme; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Target Oncol       Date:  2012-05-22       Impact factor: 4.493

6.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors:  R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

Review 7.  Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.

Authors:  Sanjay Gupta
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

8.  Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.

Authors:  S Grozinsky-Glasberg; G Kaltsas; M Kaltsatou; N Lev-Cohain; A Klimov; V Vergadis; I Uri; A I Bloom; D J Gross
Journal:  Endocrine       Date:  2018-01-30       Impact factor: 3.633

9.  Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors.

Authors:  Scott R Schell; E Ramsay Camp; James G Caridi; Irvin F Hawkins
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

Review 10.  Liver transarterial embolizations in metastatic neuroendocrine tumors.

Authors:  Louis de Mestier; Magaly Zappa; Olivia Hentic; Valérie Vilgrain; Philippe Ruszniewski
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.